Session Details
[29-29-pm]Drug design 2
Sun. Mar 29, 2026 1:10 PM - 3:10 PM JST
Sun. Mar 29, 2026 4:10 AM - 6:10 AM UTC
Sun. Mar 29, 2026 4:10 AM - 6:10 AM UTC
Room 29 (3401, Bldg. 3, Area 4 [4F])
Chair: Hidehiko Nakagawa, Miki Imanishi
[29-29-pm01S]Design, Synthesis, and Evaluation of the Anticancer Activity of Calix[4]arene-Peptide Hybrid Introducing Cationic Peptide
○Saki Sekiguchi1, Hiroki Ueda1, Hideshi Yokoyama1, Tomokatsu Ikawa2, Aisa Suzuki2, Naoyuki Aikawa3, Akinobu Kagiyama3, Shin Aoki1,2,4 (1. Fac. Pharm. Sci., Tokyo University of Science, 2. Research Institute for Biomedical Sciences, Tokyo University of Science, 3. Fac. Advanced Engineering, Tokyo University of Science, 4. Research Institute for Science & Technology, Tokyo University of Science)
[29-29-pm02S]Chemical synthesis of oligonucleotides based on the phosphorofluoridate chemistry①
○Nana Mihara1, Syuya Inoue1, Kazuho Okunishi1, Tsubasa Inokuma1, Yasufumi Fuchi2, Yuta Ito2, Yoshiyuki Hari2, Noriko Saito-Tarashima1, Noriaki Minakawa1 (1. Grad. School of Pharm. Sci., Tokushima Univ., 2. Fac. Pharm. Sci., Tokushima Bunri Univ.)
[29-29-pm03S]Chemical synthesis of oligonucleotides based on the phosphorofluoridate chemistry②
○Syuya Inoue1, Nana Mihara1, Kazuho Okunishi1, Tsubasa Inokuma1, Yasufumi Fuchi2, Yuta Ito2, Yoshiyuki Hari2, Noriko Saito-Tarashima1, Noriaki Minakawa1 (1. Grad. School of Pharm. Sci., Tokushima Univ., 2. Fac. Pharm. Sci., Tokushima Bunri Univ.)
[29-29-pm04S]Suppression of siRNA Off-Target Effects Using Base-Modified Nucleosides①
○Ayano Ebisui1, Yuhei Nogi2, Taketo Inoue2, Makoto Yahata1, Jun Tsukimoto2, Noriko Saito Tarashima2, Noriaki Minakawa2 (1. Fac. Pharm. Sci., Tokushima Univ., 2. Grad. Sch. Pharm. Sci., Tokushima Univ.)
[29-29-pm05S]Rational Design of CPP-Grafted Peptide-Based PPI Inhibitors
○Minami Fujita1,2, Tsuyoshi Konuma1, Ayaka Yoshida2, Noriaki Arakawa2, Kosuke Saito2, Yosuke Demizu1,2 (1. Grad. Sch. Med. Life Sci., Yokohama City Univ., 2. NIHS)
[29-29-pm06S]Design of Inhibitors Targeting the Symmetric Binding Pocket of STING
○Hitomi Terauchi1,2, Taiyo Toita3, Tsuyoshi Konuma3, Hideki Hara4, Genichiro Tsuji2, Syoichi Ishida3, Toru Ekimoto3, Mitsunori Ikeguchi3, Kei Terayama3, Yosuke Demizu1,2,3 (1. Grad. Sch. Med., Dent. and Pharm. Sci., Okayama Univ., 2. NIHS, 3. Grad. Sch. Med. Life. Sci., Yokohama City Univ., 4. Asahikawa Medical University)
[29-29-pm07S]Linker Length Optimization of Bispecific DNA Aptamer-Based HER2 Targeting Lysosome-Targeting Chimera (HER2-LYTAC)
○Yusei Yoda1, Eugen Potaptschuk1, Natsumi Ishimori1, Yamato Kikkawa1, Yuji Yamada1, Keisuke Hamada1 (1. Grad. Sch. Pharm. Sci., Tokyo Univ. Pharm. Life Sci.)
[29-29-pm08S]Development of novel lysosome-targeting chimera by non-covalent type Fc-IGF2 complex for target protein degradation
○Natsumi Ishimori1, Yusei Yoda1, Linda C Boshoff1, Yuji Yamada1, Yamato Kikkawa1, Keisuke Hamada1 (1. Grad. Sch. Pharm. Sci., Tokyo Univ. Pharm. Life Sci.)
[29-29-pm09S]Development of oligonucleotides that recruit U1 snRNA to promote exon inclusion
○Yuhei Nogi1, Jun Tsukimoto1, Noriko Saito Tarashima1, Noriaki Minakawa1 (1. Grad. Sch. Pharm. Sci., Tokushima Univ.)
[29-29-pm10S]Synthesis of 4'-thio-BNA/LNA nucleoside
○Taiga Sato1, Yuya Shiraki2, Jun Tsukimoto2, Noriko Saito-Tarashima2, Noriaki Minakawa2 (1. Fac. Pharm. Sci., Tokushima Univ., 2. Grad. Sch. Pharm. Sci., Tokushima Univ.)
